Medicamen Biotech Ltd (MEDICAMEQ)
🎯 Key Takeaways
- Revenue declined 21% QoQ to ₹48 in Q1FY27.
- Market Cap
- ₹443
- P/E Ratio
- 44.1
- P/B Ratio
- 1.61
- ROE
- 3.9%
- ROCE
- 4.8%
- Debt/Equity
- 0.17
- Div Yield
- 0.31%
- Promoter
- 40.5%
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 43 | 47 | 47 | 61 | 48 |
| Operating Profit | 3 | 3 | 3 | 4 | 3 |
| OPM % | 6.5% | 7.0% | 5.4% | 6.1% | 5.3% |
| Net Profit | 2 | 2 | 2 | 4 | 2 |
| EPS | ₹1.18 | ₹1.56 | ₹1.21 | ₹3.28 | ₹1.36 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 14 |
| Reserves | 200 | 203 | 262 | 262 |
| Borrowings | 33 | 20 | 48 | 39 |
| Total Liabilities | 297 | 289 | 372 | 367 |
| Fixed Assets | 87 | 88 | 84 | 85 |
| Investments | 0 | 0 | 0 | 8 |
| Total Assets | 297 | 289 | 372 | 367 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -8 |
| Investing | -1 |
| Financing | -1 |
| Net Cash Flow | -11 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 40.5% | 40.5% | 40.5% | 40.5% |
| FII | 0.1% | 0.0% | 0.1% | 0.1% |
| DII | 0.6% | 0.4% | 0.0% | 0.4% |
| Public | 33.4% | 32.2% | 32.1% | 32.1% |
| # Shareholders | 11,177 | 10,967 | 10,806 | 11,047 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Insider Trading2026-09-30Medicamen Biotech announced a director's sale of 70,000 equity shares on September 28, 2026, reducing his post-sale holding to 0.76% of total shares, …
- Announcement2026-09-28Medicamen Biotech Ltd has closed its insider trading window effective October 1, 2026, until 48 hours after announcing quarterly results for the Septe…
- 🟡 Board Meeting2026-09-28Medicamen Biotech held its 33rd AGM on September 26, 2026, where shareholders approved all eight resolutions including adoption of standalone and cons…
- 🟡 Board Meeting2026-09-26Medicamen Biotech held its 33rd AGM on 26 September 2026 via video conference, adopting audited standalone and consolidated financial statements for F…
- 🔴 annual report2026-09-03Medicamen Biotech Ltd held its 33rd AGM on September 26, 2026 via video conferencing, approving its FY2025-26 Annual Report. The company reported 18.1…
- 🔴 annual report2026-09-03Medicamen Biotech Ltd announced its 33rd AGM on September 26, 2026 via video conference, alongside filing its FY 2025-26 Integrated Annual Report. The…
- 🟡 sustainability report2026-09-03Medicamen Biotech Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 to BSE on September 3, 2026, as mandat…
- 🟡 Board Meeting2026-09-03Medicamen Biotech Ltd announced its 33rd AGM on September 26, 2026, via video conferencing, with e-voting from September 23-25. The meeting will adopt…
- 🟡 Board Meeting2026-08-18Medicamen Biotech announced that its 33rd Annual General Meeting will be held on September 19, 2026, with book closure from September 20 to 26, 2026, …
- share transfer2026-07-28Medicamen Biotech Limited confirmed that its registrar and share transfer agent submitted dematerialization and rematerialization details for the quar…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when MEDICAMEQ files new disclosures
Track MEDICAMEQ filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track MEDICAMEQ — FreeFree account · 2 AI queries/day